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products modified low density lipoprotein
inhibits atherosclerosis progression in diabetic
apoE and LDLR null mice
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Bengtsson Eva4, Nilsson Jan4, Chun Liang1* and Zonggui Wu1*Abstract
Background: Diabetes accelerates atherosclerosis through undefined molecular mechanisms. Hyperglycemia
induces formation of advanced glycation end product (AGE)-modified low-density lipoprotein (LDL). Anti-AGE-LDL
autoantibodies favor atherosclerosis (AS) progression in humans, while anti oxidized LDL immunization inhibits AS
in hypercholesterolemic, non-diabetic mice. We here investigated if AGE-LDL immunization protects against AS in
diabetic mice.
Methods: After diabetes induction with streptozotocin and high fat diet, both low density lipoprotein receptor
(LDLR)−/− and apoE female mice were randomized to: AGE-LDL immunization with aluminum hydroxide (Alum)
adjuvant; Alum alone; or PBS.
Results: AGE-LDL immunization: significantly reduced AS; induced specific plasma IgM and IgG antibodies;
upregulated splenic Th2, Treg and IL-10 levels, without altering Th1 or Th17 cells; and increased serum high density
lipoprotein(HDL) while numerically lowering HbA1c levels.
Conclusions: Subcutaneous immunization with AGE-LDL significantly inhibits atherosclerosis progression in
hyperlipidemic diabetic mice possibly through activation of specific humoral and cell mediated immune responses
and metabolic control improvement.
Keywords: Immunization, Advanced glycation end products, Low density lipoprotein, Atherosclerosis, DiabetesIntroduction
Diabetes mellitus through as yet undefined mechanisms
worsens short and long term clinical prognosis of car-
diovascular disease (CVD) manifested as asymptomatic
ischemic events and increased morbidity and mortality
[1]. No current therapy specifically targets diabetes-
induced CVD, however, promising immunization stra-
tegies against AS have been developed [2-9], supported
by: association between autoantibodies against oxidized
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unless otherwise stated.humans [10]; reduced AS lesion formation in mice after
ox-LDL immunization [11]; and AS regression induction
in Apobec-1−/− /LDL receptor (LDLR) null mice by re-
combinant antibodies against aldehyde-modified apoB100
peptide 661–680 [12]. Diabetes is associated with increased
protein glycation and generation of AGE; in particular,
AGE-LDL appears suitable as basis for a vaccine against
AS in diabetes because it accelerates AS progression via
different signaling pathways [13-21], and similar to ox-
LDL, immune complexes containing anti-AGE-LDL auto-
antibodies in diabetics are associated with AS [22,23]. In
this study, we immunized diabetic apoE−/− and LDLR−/−
mice with AGE-LDL to assess ability of this strategy to re-
duce AS.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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LDL isolation and glycation
LDL was isolated from pooled plasma of healthy volun-
teers by ultracentrifugation. Glycated LDL was prepared
by incubation of LDL with 0.2 M glucose for 4 weeks at
37°C with antioxidants (1 mg/ml EDTA and 1 μM butyl-
ated hydroxytoluene) under sterile conditions, and exten-
sively dialyzed before use. Oxidized LDL (ox-LDL) was
prepared by incubating native LDL (nLDL) under sterile
conditions with 5 μM CuCl2 without antioxidant protec-
tion for 3 hours as previously described [24]. The oxida-
tive reaction was stopped by addition of EDTA, dialyzed
extensively against PBS under sterile conditions, stored at
4°C, and used within 7 days. Protein glycation was mea-
sured by the thiobarbituric assay (TBA) and expressed as
nmoles of 5-hydroxymethylfurfural (HMF) per mg protein
[25] and by trinitrobenzene sulphonic acid assay (TNBSA)
[26]. Protein concentration was measured by a modified
Lowry method as previously reported [27]. LDL oxidation
was assayed by measuring the thiobarbituric acid reactive
substances (TBARS) and carbonyls [28]. The electric
charge of LDLs (including nLDL, AGE-LDL and ox-LDL)
were evaluated by agarose gel electrophoresis as pre-
viously reported [29].
Ethics statement
The study had been reviewed by the ethics committee of
Second Military Medical University, and performed in
accordance with the ethical standards as per the 1964
Declaration of Helsinki. Informed consent was obtained
from all volunteers of plasma collection.
Mice, immunization, and tissue preparation
Local Animal Care and Use Committee at Second Military
Medical University approved the entire experimental
protocol used in the study. All surgery was performed
under anesthesia, and all efforts were made to minimize
suffering in compliance with the ARRIVE guidelines on
animal research [30].
Female apoE−/− and LDLR−/− mice on a C57BL/6
background from Jackson Laboratory (USA) were used
(n = 36, 3 groups of 12 apoE null mice and n = 30, 3
groups of 10 LDLR null mice). From 6 weeks of age
mice were fed ad libitum a high-cholesterol diet (0.15%
cholesterol, 21% fat); made diabetic with intraperitoneal
injections of streptozotocin according to a modified
protocol (50 mg/kg per day dissolved in 200 μl citrate
buffer, pH 7.4 for 7 days) [31]; and monitored for blood
glucose and HbA1c once weekly until euthanized. At
9 weeks of age the mice were injected subcutaneously
(first immunization) in the dorsal area between scapulas,
followed by a booster at 11, 13 and 15 weeks of age
(Additional file 1: Figure S1). Aluminum hydroxide
(Alum) (Biosecter, Denmark) was used as adjuvant andmixed with AGE-LDL (25 μg/dose) with 1:1 ratio in
volume. The mixture with Alum was freshly prepared
prior to each immunization. Alum alone or citrate buffer
was used as controls.
All mice were euthanized at 24 weeks of age by exsan-
guination through cardiac puncture under anesthesia with
pentobarbital sodium administered intraperitoneally.
Spleens were immediately collected and immersed in pre-
pared cold PBS containing antibiotics (Life, USA) for flow
cytometry and real time PCR analysis without perfusion.
After whole-body perfusion with phosphate-buffered sa-
line (PBS) followed by Histochoice (Amresco), the heart
and the aortic arch were dissected out and stored in
Histochoice at 4°C until processing. The aorta was dis-
sected free of external fat and connective tissue, cut
longitudinally, and mounted en face, lumen side up, on
polylysine and 3-aminopropyltriethoxysilane (APES)-
coated slides (Bolster, Wuhan).
Aorta staining
En face preparations of the aorta were washed in distilled
water, dipped in 78% methanol, and stained for 40 minutes
in 0.16% Oil-Red-O solution as previously described [32].
The cover slides were mounted with a water-soluble
mounting media. Lipids are stained red. The slides were
scanned and digitized with Epson 4990, and stained
plaque areas in total aorta were quantified blindly by com-
puter aided morphometry software (Image J).
Analysis of plaques
Staining and quantification of plaque area in aorta and
subvalvular plaque macrophage content were done as
previously described [32]. The aortic arch was embedded
in OCT (Tissue-Tek, Sakura, Japan) and 10-μm frozen
sections were collected. The sections were dipped briefly
in 60% isopropanol and stained in 0.24% Oil Red-O in
60% isopropanol for 20 minutes. Sections were briefly
washed in 60% isopropanol, then washed in water and
counter-stained with hematoxylin. Plaque collagen con-
tent was assessed with Masson’s trichrome staining
kits (Maximbio, Fuzhou, China). Slides used for staining
with rat anti-mouse MOMA-2 (monocyte/macrophage,
MAB1852, Millipore USA) and alpha-smooth muscle
actin antibodies (A5228, Sigma, USA) diluted in 10% rat
serum in PBS incubated at 4°C overnight, were first fixed
in ice-cold acetone for 10 minutes, washed in PBS for
5 minutes, and then blocked with 10% mouse serum in
PBS for 30 minutes and quickly dipped in PBS. Bio-
tinylated rabbit anti-rat IgG was used as secondary anti-
body and DAB detection kit for color development
(Maximbio, Fuzhou, China). Omissions of the primary
antibodies were used as negative control [33]. Stained
area was quantified blindly by computer aided mor-
phometry software (Image J).
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Blood samples were collected by either tail-vein nick
(glucose) or cardiac puncture (HbA1c, lipid and cyto-
kine analysis). Non-fasting glucose levels were measured
using an Accu-Chek Compact Meter (Roche Diagnostics,
Indianapolis, IN) once a week. HbA1c levels were mea-
sured using A1cNow +Monitors (Metrika, Sunnyvale,
CA) [34]. Total plasma cholesterol was quantified by
colorimetric assays (Infinity Total Cholesterol Reagent;
Sigma). Plasma high density lipoprotein cholesterol
(HDL-C) was determined by precipitating non–HDL-C
(Wako Diagnostic) and then assaying the remaining cho-
lesterol with the Infinity Total Cholesterol Reagent. Low
density lipoprotein cholesterol (LDL-C) was determined
by L-type LDL-C kit from Wako Chemicals (Richmond,
Virginia, USA). IL-10, TGF-β and IFN-γ in serum and cy-
tokines in splenocyte supernatants were measured with
Milliplex kits (Millipore, USA) in a Luminex Multiplexing
Instrument according to manufacturer’s instructions.
Antibody assays
AGE-modified LDL were used for coating (200 μg/mL of
each in PBS pH 7.4) microtiter plates (Nunc MaxiSorp,
Denmark) in an overnight incubation at 4°C. Coated
plates were washed with PBS with 0.05% Tween-20 and
thereafter blocked with SuperBlock in Tris-buffered saline
for 5 minutes at room temperature followed by an incuba-
tion of mouse serum diluted 1:50 in TBS-0.05% Tween-20
for 2 hours at room temperature and overnight at 4°C.
After washing, bound antibodies were detected by using
biotinylated goat anti-mouse IgM (AP500B, Millipore,
USA) or IgG (B7264, Sigma, USA) or rat anti-mouse IgG1
or IgG2a secondary antibodies (RMG115 and RMG2a15,
Millipore, USA) that were incubated for 2 hours at room
temperature. The plates were washed, and bound bio-
tinylated antibodies were detected by alkaline phos-
phatase–conjugated streptavidin (V559C, Promega, USA).
The color reaction was developed using phosphatase sub-
strate kit (Pierce). Absorbance at 405 nm was measured
after 1 hour incubation at room temperature. Mean values
were calculated after subtraction of background absor-
bance (n = 4 per mouse).
Flow cytometry and intracellular cytokine staining
Flow cytometry was performed on a FACS Calibur (BD,
USA) after staining with appropriate antibodies; data were
analyzed using Flowjo software (USA). Primary labeled
antibodies used were from BD Biosciences (anti-CD4) or
from eBioscience (anti-FoxP3). To characterize the cyto-
kine expression profiles of splenic CD4+ T cells from dif-
ferent vaccinated mice, cell suspensions were prepared as
described before and evaluated by intracellular cytokine
staining and FACS analysis. Briefly, splenocytes were pre-
pared by mechanical disruption followed by incubation inerythrocyte lysis buffer (Qiagen, USA) and extensively
washed. 2 × 106 spleen were stimulated for 4 h at 37°C in
7.5% CO2 with PMA (phorbol 12-myristate 13-acetate;
50 ng/ml, Sigma), ionomycin (500 ng/ml; Sigma) and
monensin (2 ng/ml; Biolegend). All cells were incubated
with FcγR block (BD Bioscience) followed by surface
(anti-CD4, Biolegend) and then intracellular staining of
IFNγ (eBioscience), IL-4, or IL-17 (Biolegend) and FoxP3
(eBioscience) according to manufacturer’s instructions.
Lymphocytes were firstly gated using forward and side
scatter plots, and then intracellular staining was per-
formed within only CD4 positive T cells to characterize
T-cell subtype (IFNγ+, IL-4+, or/and IL-17+, while FoxP3+
in CD4+CD25+). Fluorescence minus one (FMO) controls
were stained in parallel using the panel of antibodies with
sequential omission of one antibody, with the exception of
the anti-Foxp3 antibody, which was replaced by an isotype
control. One million cells, washed twice in PBS before
fixation and permeabilization, were used for each test.
Real-time polymerase chain reaction
RNA was isolated from spleens using the RNeasy kit from
Qiagen (Hilden, Germany). Purity of obtained RNA was
estimated by Nanodrop from Thermo (USA). RNA with
an A260/A280 > 1.8 was used for cDNA synthesis. Reverse
transcription was performed with PrimeScript™ 1st Strand
cDNA Synthesis Kit (Takara, Japan) and cDNA amplified
by iQ SYBR Green real-time PCR Supermix (Bio-rad,
USA) using primers (Life Technology, USA) for FoxP3,
IL-10, TGF-β, IFN-γ and Glyceraldehyde 3-phosphate de-
hydrogenase (GAPDH) in an CFX Connect real-time PCR
detection system from Bio-rad. Data were analyzed based
on relative expression method using the formula 2-ΔΔCT ,
where ΔΔCT =ΔCT (sample) – ΔCT (calibrator = average
CT values of all samples within each group), and ΔCT is
the CT of the housekeeping gene (GAPDH) subtracted
from the CT of the target gene.
Statistical analysis
Data are presented as mean ± standard deviation. Com-
parison among groups was performed using one-way
ANOVA and Turkey post test using GraphPad Prism
5.01 (Graphpad software, La Jolla, CA, USA). Statistical
significance was considered at the level p < 0.05.
Results
Characterization of AGE-LDL
Because in vivo glycation of LDL is very complex involv-
ing nonenzymatic reaction of glucose and its metabolites
with the free amino groups of lysine [35], nLDL and ox-
LDL were used as reference to characterize the AGE-
LDL used as immunization agent. AGE-LDL showed
extensive apoB glycation (TBA) and high lipid peroxide
levels (TBARS assay); glycation was increased by >4-fold
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or >6-fold (1.82 ± 0.31 vs. 0.30 ± 0.21 nmoles MDA/mg
protein, P < 0.05) relative to nLDL. TNBSA assays
showed 29% reduction in free amino groups of apoB in
AGE-LDL relative to n- or ox-LDL (0.32 ± 0.04 AU vs.
0.45 ± 0.08 AU or 0.40 ± 0.07 AU, respectively, P < 0.05)
consistent with irreversible protein glycation (Table 1);
while Rf measurement showed a 45% increase for AGE-
LDL (0.74 ± 0.05, P < 0.05) and a 24% increase for ox-LDL
(0.63 ± 0.08, P < 0.05) compared with nLDL (0.51 ± 0.05),
indicating loss of positive charges due the glycation of Lys
and Arg residues. In vitro generated AGE-LDL therefore
had similar features to those of AGE-LDL collected from
plasma in vivo and could be used as potential vaccination
antigen.
Immunization with AGE-LDL inhibits atherosclerosis in
murine diabetic models
Immunization with AGE-LDL using Alum as adjuvant
resulted in a significant reduction in atherosclerotic
lesion burden compared to mice immunized with PBS
control (76% in LDLR null diabetes mellitus(DM) mice,
p < 0.01; and 43% in apoE null DM mice, p < 0.01) or
Alum alone (50% in LDLR null DM mice, p < 0.05; and
20% in apoE null DM mice, p < 0.05) (Figure 1). AGE-
LDL immunization also reduced lesion area in the aortic
root (42% in apoE null DM mice, p < 0.05; 40% in LDLR
null DM mice, p < 0.05) compared with PBS controls
(Figure 2A-B). Atherosclerotic lesions were only signifi-
cantly attenuated by administration of Alum adjuvant
compared with PBS controls in LDLR−/− DM mice but
not in apoE−/− DM mice, which was consistent with
previously reported anti-atherosclerotic effects of Alum
therapy [36] and a discrepancy in vaccination response
between the two hypercholesterolemic mouse models.
However, quantitative immunohistochemical analysis of
markers for macrophages (MOMA-2), smooth muscle
cells (alpha-smooth muscle actin) or collagen (Masson)
showed that the immunization strategy did not signifi-
cantly alter the composition of the lesions (Figure 2C-D).
Immunization with AGE-LDL increases plasma HDL levels
Immunization with AGE-LDL using Alum adjuvant in-
creased serum HDL levels both in apoE and LDLR DMTable 1 Characterization of AGE-LDL
nLDL
TBA (nmoles HMF/mg protein) 1.92 ± 1.30
TNBSA (AU) 0.45 ± 0.08
TBARS (nmoles MDA/mg protein) 0.30 ± 0.21
Rf (cm) 0.51 ± 0.05
*indicates p < 0.05 vs. nLDL, **indicates p < 0.01 vs. nLDL and #indicates p < 0.05 vs.
HMF: 5-hydroxymethylfurfural; TNBSA: trinitrobenzene sulphonic acid assay; TBARS:
electrophoretic mobility by agarose gel electrophoresis.mice (151.97 ± 25.08 mg/dl and 153.91 ± 21.14 mg/dl)
compared with PBS controls (113.30 ± 15.47 mg/dl and
127.11 ± 21.33 mg/dl) (P < 0.05), without significant ef-
fects on body weight, serum cholesterol, or non-fasting
glucose levels. Although HbA1c levels were not signifi-
cantly different among groups, numerically lower HbA1c
level was found in both mouse models (p = 0.068 in
apoE DM mice and p = 0.073 in LDLR DM mice for%
data, while p = 0.059 in apoE ones and p = 0.074 in
LDLR ones for mmol/L data). The data suggest that part
of the atheroprotective effects of vaccination with AGE-
LDL could be derived from improved metabolic control
(Table 2).
Immunization with AGE-LDL induces systemic humoral
and cellular immune responses
Immunization with AGE-LDL using Alum as adjuvant
induced significantly elevated titers of IgG and IgM anti-
bodies against AGE-LDL in both diabetic apoE −/− and
LDLR −/− mice (Figure 3A). Total IgG and IgM levels
were not influenced by either treatment. Immunization
with Alum alone did not induce AGE-LDL-specific IgM
and IgG titers implying that the humoral immune re-
sponses were specific to the antigen AGE-LDL and not
associated with adjuvant. Further analysis showed that
the increase of IgG level was mostly derived from that of
IgG1, associated with a Th2 response, which was signifi-
cantly increased in serum from AGE-LDL immunized
mice compared with serum from control or Alum adju-
vant treated groups (p < 0.05, Figure 3B). Modestly in-
creased anti-AGE-LDL IgG level was observed in Alum
adjuvant-immunized mice, which might be associated
with antigen capture as previously reported [36]. The
IgG1/IgG2a ratio of anti-AGE-LDL antibodies was sig-
nificantly increased in both models receiving AGE-LDL
vaccination compared with Alum and PBS control recipi-
ents (p < 0.05 and p < 0.01 respectively) (Figure 3C), with
increased Th2 levels without significant change of Th1.
Data from flow cytometry analysis showed that com-
bined vaccination with Alum and AGE-LDL significantly
increased the proportion of Th2 and Treg CD4+ T cells
subsets in spleen, characterized by intracellular staining
for IL-4 and FoxP3, while no significant differences were
shown in Th1 and Th17 cells compared with thoseox-LDL AGE-LDL
4.41 ± 1.22* 7.35 ± 0.83**#
0.40 ± 0.07* 0.32 ± 0.04*
4.17 ± 0.06** 1.82 ± 0.31*#
0.63 ± 0.08* 0.74 ± 0.05*
ox-LDL; nLDL: native low density lipoprotein; TBA: thiobarbituric assay;
thiobarbituric acid reactive substances; MDA: malondialdehyde; Rf: relative
Figure 1 Immunization with AGE-LDL using Alum as adjuvant reduced atherosclerotic lesion burden of diabetic apoE −/− and LDLR-/
mice. A and B, Representative photomicrographs showing oil red O stained en face preparations of aortas (n = 10 in each group). C. Percentage of
plaque area of total aortic area of diabetic apoE−/− and LDLR−/− mice treated with Alum adjuvant (bar with stripes), Alum+ AGE-LDL immunization
(black bar), and PBS treated controls (white bar). Mean ± SD values are shown. *indicates p < 0.05 vs. control, **indicates p < 0.01 vs. control, #indicates
p < 0.05 vs. Alum adjuvant.
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vant treated groups (Figure 4A-C), although numerically
lower Th17 for apoE or LDLR null mice was shown in
AGE-LDL immunized vs. Alum alone treated mice
(p = 0.08 in apoE DM mice and p = 0.075 in LDLR DM
mice).
Immunization with AGE-LDL increases splenic FoxP3 and
IL-10 mRNA levels and cytokine secretion
Real-time PCR analysis of splenocytes from apoE and
LDLR null mice immunized with AGE-LDL showed sig-
nificant increases in FoxP3 and IL-10 mRNA levels com-
pared to both PBS and Alum treated mouse groups
(Figure 5A). Alum alone also induced an increase inIL-10 and Foxp3 mRNA levels. Protein level of IL-10
was significantly elevated in AGE-LDL compared with
Alum alone treated mice as well as in Alum treated mice
versus control group (Figure 5B), which was consistent
with real-time PCR data. In addition, there was nume-
rically higher transforming growth factor-beta (TGF-β)
(p = 0.23) mRNA level in Alum treated mice compared
with PBS controls (Figure 5A).
Discussion
The present study provides a novel strategy, namely sub-
cutaneous administration of AGE-LDL using Alum as
adjuvant, to induce protective immunity against athero-
sclerosis in two complex animal models with diabetes
Figure 2 Immunization with AGE-LDL and Alum adjuvant did not significantly change atherosclerotic lesion composition in the aortic
root of diabetic apoE −/− and LDLR−/− mice. A and C, Representative photomicrographs showing Oil-red O (scale bar = 100 μm) and collagen
(Masson), macrophage, and smooth muscle cell (SMA) stained aortic root sections (scale bar = 120 μm) from each group (n = 6 per group).
B. Oil-red O stained area in the aortic root: white circles represent animals from the PBS-treated control group, black squares represent animals
from the Alum adjuvant group, and white squares represent animals from the AGE-LDL + Alum treated group. *indicates p < 0.05 vs. control.
D, Quantification of collagen, macrophages and smooth muscle cells from the 3 groups are shown: white bars represent animals from the control
group, bars with stripes represent animals from the Alum adjuvant group, and black bars represent animals from AGE-LDL + Alum treated group.
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attributed to increased levels of HDL, antigen-specific
Th2 antibodies and IL-10, and expansion of antigen-
specific CD4+ Treg cells.
Mechanisms behind the vaccination strategy
Only diabetic atherosclerotic model mice were chosen in
the present study to evaluate the efficacy of the vaccin-
ation strategy, which was based on previous studies
showing that increased level of AGEs was found mainly
in patients with diabetes and end-stage renal diseases
[37-39] and contributed to accelerated atherosclerosis.
In addition to the above patient populations, data from
Japan Assessment of Pitavastatin and Atorvastatin in
Acute Coronary Syndrome (JAPAN-ACS) trial showed
that high baseline AGEs levels were also associated with
plaque progression among patients with AS independ-
ently of DM [40]. Meanwhile AGEs was shown to be re-
lated to long-term glucose control and other oxidative
stresses in acute coronary syndrome [40] and in thedevelopment of coronary artery calcification in individ-
uals with type 1 DM [41].
Thus it is likely that immunization with AGE-LDL
would have its most prominent effect in diabetic mice.
However, because glycation of LDL, and especially of
small-dense LDL, also has been found in patients with-
out diabetes [42], and there is some cross-reactivity be-
tween ox-LDL and AGE-LDL antibodies [22], it cannot
be excluded that immunization with AGE-LDL also
could reduce atherosclerosis, albeit to a lesser extent, in
animal models without diabetes. However, this needs to
be further explored.
Immunization with different antigens inhibits athero-
sclerosis progression in atherosclerosis-prone animal
models [6,9,32,35,43], however, there are scarce data on
efficacy of such immunization strategies in diabetic ani-
mal models with atherosclerotic disease. Research in this
field is highly important because diabetics account for a
very large proportion of patients requiring cardiovascu-
lar therapy; incidence of diabetes continues to rapidly
Table 2 Weight, cholesterol, average plasma non-fasting glucose and HbA1c levels
Group Weight (g) Cholesterol HDL-C LDL-C Average non-fast
glucose
HbA1c
(mg/dl) (mg/dl) (mg/dl) (mg/dl) (%) (mmol/L)
apoE −/− DM Control (n = 12) 28.11±1.40 1082.46±137.40 113.30±15.47 767.10±45.40 547.99±36.85 9.10±0.45 76.00 ± 4.93
Alum (n = 12) 28.64±2.53 1072.06±144.53 136.12±23.20 752.57±55.88 557.63±29.55 8.76±0.40 72.13 ± 4.29
Alum + AGE-LDL (n = 12) 28.17±2.43 1084.85±138.43 151.97±25.08* 739.37±44.92 548.53±44.33 8.58±0.43 70.25 ± 4.56
LDLR −/− DM Control (n = 10) 27.11±1.35 1077.65±115.22 127.11±21.33 781.86±44.43 531.51±42.40 8.72±0.16 71.88 ± 1.73
Alum (n = 10) 28.03±2.11 1085.10±154.39 138.44±20.42 778.58±33.78 548.52±51.53 8.67±0.17 71.38 ± 1.85
Alum + AGE-LDL (n = 10) 28.21±1.03 1090.24±143.53 153.91±21.14* 768.55±44.97 536.35±42.65 8.52±0.13 69.88 ± 1.55
P value n.s. n.s. n.s. n.s. n.s. n.s.
















Figure 3 Serum titers of IgG, IgM, IgG1 and IgG2a antibodies. A. ELISA analysis of titers of IgG, IgM, and specific anti-AGE-LDL IgG and IgM
antibodies in sera from diabetic apoE−/− and LDLR−/− mice (n = 10 per group) treated with Alum adjuvant (bar with stripes), AGE-LDL + Alum
adjuvant (black bar) or PBS controls (white bar). B. ELISA analysis of specific IgG1 and IgG2a antibodies against AGE-LDL in sera from diabetic
apoE−/− and LDLR−/− mice treated with Alum adjuvant, AGE-LDL + Alum adjuvant or PBS controls. C shows the ratio of serum IgG1/IgG2a
antibodies among three groups. *indicates p < 0.05 vs. control, **indicates p < 0.01 vs. control, and #indicates p < 0.05 vs. Alum.
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[44,45]; and diabetes is associated with increased risk of
cardiovascular disease.
As the main core etiological factors, data from recent
studies confirmed that blockade of the positive feedback
loop between AGE-receptor for advanced glycation end
products (RAGE) axis by dipeptidyl peptidase-4 inhibi-
tors might be a novel therapeutic target for vascular in-
jury in diabetes [46], and furthermore exendin-4 could
exert cardioprotective effect against diabetic cardio-
myopathy, which may be associated with the inhibition
of RAGE expression [47]. Except for AGE-RAGE, hepa-
ranase is another target gene of the diabetic nephropathy
mediators albumin and AGE [48], which was proved
by experimental evidence to play a key role in AGEs-
induced macrophage migration associated with inflam-
mation in diabetic vascular complication [49]. All the
above might be the potential mechanism of our vac-
cination strategies.
The present findings not only confirm the efficacy AGE-
LDL immunization in inhibiting atherosclerosis pro-
gression, but also show some interesting and unexpected
findings: 1) Increased serum HDL and numerically lowerHbA1c levels in mice receiving AGE-LDL vaccination,
although glucose levels did not differ significantly among
groups; improved metabolic control therefore might be
one of the protective effects of vaccination in accordance
with a previous report showing anti-diabetic effects of all-
trans retinoic acid secondary to increasing Treg levels
[50,51]. 2) Although apoE−/− and LDLR−/− mice are used
as atherosclerosis-prone mouse models, mechanism of ath-
erosclerosis progression differs between the two models.
The present study showed that vaccination with Alum sig-
nificantly decreased plaque burden in subvalvular aorta
only in LDLR null DM mice but not in apoE null DM
mice, which might reflect the intrinsic difference of genetic
background between the two mouse models. A previous
study showed that targeted deletion of Group V secretory
phospholipase A2 could significantly alter atherosclerotic
lesion area in LDLR−/− mice but not apoE−/− mice, which
was attributed to different composition and oxidative sta-
tus of LDL between such strains [52], and might also lead
to the discrepancy of atherosclerosis burden observed in
our study. However, because immunization with AGE-
LDL and Alum as adjuvant has similar effects and mecha-
nisms in both models, the immunization strategy based
Figure 4 T cell subsets in spleen after immunization. A. Flow cytometry analysis strategies of T cell subsets in spleen, B and C. Levels of
T cell subset are shown as percentages of cytokine producing cells (Interferon-γ, IL-17 and IL-4) per CD4+ T cells, and FoxP3 positive cells per
CD4+ CD25+ T cells stimulated with AGE-LDL for each of the three groups (white bars = controls, bars with stripes = Alum adjuvant and black
bars = AGE-LDL + Alum adjuvant, n = 10 per group). *indicates p < 0.05 vs. control, **indicates p < 0.01 vs. control, and #indicates p < 0.05
vs. Alum.
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development.
Current strategies against atherosclerosis
Several immunization strategies against atherosclerosis
have been developed, and different techniques and targets
have been chosen to determine their protective effect inmice and rabbits [53,54]. Among these antigens, apolipo-
protein B100 (ApoB100, CVX-210-H) and the cholestero-
lester transferase protein (CETP) were mostly chosen and
shown to be well-tolerated among patients [55]. However,
there were several limitations to their ability to induce
protective immunity against atherosclerosis, including in-
sufficient immunogenicity; further formulations with
Figure 5 Immunization with AGE-LDL increased IL-4, FoxP3 and IL-10 levels in spleens from diabetic mice. (A) mRNA transcript ratios
based on GAPDH expression are shown for each gene of interest for all 3 groups (n = 10 per group). (B) Secretion patterns of cytokines
determined in supernatants derived from splenocytes stimulated with AGE-LDL among groups were analyzed with milliplex assay. White bars =
controls, bars with stripes = Alum adjuvant and black bars = AGE-LDL + Alum adjuvant. *indicates p < 0.05 vs. control, **indicates p < 0.01 vs.
control, and #indicates p < 0.05 vs. Alum.
Zhu et al. Cardiovascular Diabetology 2014, 13:151 Page 10 of 12
http://www.cardiab.com/content/13/1/151different carriers or adjuvants need to be tested. In our
study, Alum was chosen to enhance the immunological ef-
fects of AGE-LDL because it 1) is an adjuvant that has be
used in humans for many years; and 2) has been proven to
mediate beneficial effects against atherosclerosis by cap-
turing oxidized LDL and activating Tregs [36].
Conclusion
The present study showed that combined treatment with
human AGE-LDL and Alum adjuvant induces effective
immunity against atherosclerotic progression in diabetic
animal models with atherosclerosis, possibly mediated
by activation of protective autoantibodies production
and Tregs, as indicated by increased AGE-LDL specific
IgM and IgG titers and Foxp3 and IL-10 expression,
respectively. Study results also indicate that such treat-
ment might be useful to improve metabolic status, as
shown by increased HDL and numerically lower HbA1c
levels, although the mechanism for the metabolicmodulation remains unknown. Vaccination with AGE-
LDL potentially offers a novel approach for treatment of
atherosclerosis in patients with diabetes; however, re-
sults of the present study need to be interpreted with
due caution and further research is warranted on safety
and efficacy.Additional file
Additional file 1: Figure S1. Detailed experimental protocol. The
experimental design of studies utilized three groups of female apoE
and LDLr-/- mice at 6 weeks of age. Mice were fed ad libitum a
high-cholesterol diet and made diabetic with intraperitoneal injections of
streptozotocin for 7 days; and monitored for blood glucose and HbA1c
once weekly until euthanized. At 9 weeks of age the mice were injected
subcutaneously (first immunization) in the dorsal area between scapulas,
followed by a booster at 11, 13 and 15 weeks of age. Aluminum
hydroxide (Alum) (Biosecter, Denmark) was used as adjuvant and mixed
with AGE-LDL (25 μg/dose) with 1:1 ratio in volume. Alum alone or citrate
buffer was used as controls. All mice were euthanized at 24 weeks of age
to analyze atherosclerosis burden and immunity response.
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